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Photodynamic therapy (PDT), which is based on the activation of photosensitizers
with light, can be used to reduce plaque burden. We hypothesized that intra-arterial
photosensitizer administration and photo-activation will lead to high and rapid
accumulation within the plaque with reduced systemic adverse effects. Thus, this
“intra-arterial” PDT would be expected to have less side effects and due to the short
time involved would be compatible with percutaneous coronary interventions.
Aim: We characterized the dose-dependent uptake and efficacy of intra-arterial PDT
using Liposomal Verteporfin (Visudyne®), efficient for cancer-PDT but not tested before
for PDT of atherosclerosis.
Methods and Results: Visudyne® (100, 200, and 500 ng/ml) was perfused for
5–30min in atherosclerotic aorta isolated from ApoE−/− mice. The fluorescence Intensity
(FI) after 15min of Visudyne® perfusion increased with doses of 100 (FI-5.5 ± 1.8), 200
(FI-31.9± 1.9) or 500 ng/ml (FI-42.9± 1.2). Visudyne® (500 ng/ml) uptake also increased
with the administration time from 5min (FI-9.8± 2.5) to 10min (FI-23.3± 3.0) and 15min
(FI-42.9 ± 3.4) before reaching saturation at 30min (FI-39.3 ± 2.4) contact. Intra-arterial
PDT (Fluence: 100 and 200 J/cm2, irradiance-334mW/cm2) was applied immediately
after Visudyne® perfusion (500 ng/ml for 15min) using a cylindrical light diffuser coupled
to a diode laser (690 nm). PDT led to an increase of ROS (Dihydroethidium; FI-6.9 ± 1.8,
25.3 ± 5.5, 43.4 ± 13.9) and apoptotic cells (TUNEL; 2.5 ± 1.6, 41.3 ± 15.3, 58.9 ±
6%), mainly plaque macrophages (immunostaining; 0.3 ± 0.2, 37.6 ± 6.4, 45.3 ± 5.4%)
respectively without laser irradiation, or at 100 and 200 J/cm2. Limited apoptosis was
observed in the medial wall (0.5± 0.2, 8.5± 4.7, 15.3± 12.7%). Finally, Visudyne®-PDT
was found to be associated with reduced vessel functionality (Myogram).
Conclusion: We demonstrated that sufficient accumulation of Visudyne® within plaque
could be achieved in short-time and therefore validated the feasibility of local intravascular
administration of photosensitizer. Intra-arterial Visudyne®-PDT preferentially affected
plaque macrophages and may therefore alter the dynamic progression of plaque
development.
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INTRODUCTION
Acute coronary syndrome (ACS) is a life-threatening condition
resulting from rupture of vulnerable atherosclerotic plaque
(Gotlieb, 2005). The optimal medical therapy currently available
with statins prevents only 20–30% of cardiovascular events
(Kapur and Musunuru, 2008). Dual anti platelet therapy (DAPT)
with aspirin plus clopidogrel, prasugrel or ticagrelor, for up to
12 months after ACS has been shown to improve outcomes
after the cardiovascular event (Yusuf et al., 2001; Davis et al.,
2015). However, DAPT is often associated with increased risk of
bleeding (Clappers et al., 2007; Fanari et al., 2016). Percutaneous
coronary intervention (PCI) with balloon angioplasty, often
followed by stent implantation is the most commonly performed
procedure for the reopening of an occluded artery. Besides
restenosis and stent related problems (Kuchulakanti et al.,
2006; Gogas et al., 2014), this procedure is mainly used
on highly stenosed plaques. Less stenosed plaques, diffused
over long segments of artery, are often left untreated. These
untreated plaques continue to evolve and may eventually rupture
(Skowasch et al., 2005; Moulias and Alexopoulos, 2011). Further
interventions, either standalone or in conjunction with existing
procedures, are emerging for management of atherosclerosis
(Kalanuria et al., 2012; Riccioni and Sblendorio, 2012). Among
them, photodynamic therapy (PDT) has been shown to prevent
atherosclerotic plaque progression (Usui et al., 1999; Peng et al.,
2011). PDT generally involves either topical or, mostly, systemic
administration of a photosensitizer which is allowed to circulate
for a specific period of time to accumulation, in our case, in
atherosclerotic lesions. This time period is often referred to
as drug-light interval (DLI). Activation of the photosensitizer
with visible light of a specific wavelength generates cytotoxic
reactive oxygen species (ROS; Zhu et al., 2015). These ROS
oxidize essential tissue components and can eventually induce
cell death in tissue. Application of PDT for atherosclerotic
plaque treatment has faced some drawbacks due to the non-
specific accumulation of the photosensitizer in the skin, leading
to cutaneous photosensitivity (Wooten et al., 1988; Dougherty
et al., 1990; Wagnieres et al., 1998). Another major hurdle for
the clinical use of PDT for cancerous tissue (Braichotte D. et al.,
1995; Braichotte D. R. et al., 1995; Zellweger et al., 2000) or
particularly for the management of atherosclerosis is long DLI
(from 3 to 24 h) after systemic injection with most of the tested
PSs (Kereiakes et al., 2003; Tawakol et al., 2006). This puts PDT
out of the scope for cases where it is used alongside the treatment
of acute myocardial infarction. A short DLI is therefore critically
important for its applicability to treat those cases.
Besides DLI, accurate and efficient delivery of light is
also important for the activation of photosensitizers. Previous
reports indicated that external illumination of the artery
using Talaporfin sodium as a photosensitizer resulted into
photo toxicity of the irradiated site, however the contralateral
walls show limited photo toxicity (Wakamatsu et al., 2005).
Intra vascular irradiation circumvents this shortcoming. Intra-
arterial photo activation enables circumferential, controlled,
and homogeneous illumination of the atherosclerotic artery. In
addition, illumination length with our present setup can vary
from 1 to 7 cm and even longer light/drug applications are
possible. This permits to treat much longer segments of the
artery as compared to stents. We hypothesized that local delivery
of photosensitizer using an intravascular catheter followed by
intravascular illumination may be performed during or just
after a PCI procedure and stent implantation. Thus, this “intra-
arterial PDT” would be expected to have fewer side effects and
due to the short time involved would be compatible with PCI
procedures. Combining PCI with PDTmay reduce restenosis and
may permit the preventive treatment of non-stented vulnerable
plaque in order to reduce further coronary events. Furthermore,
as the main parameter of PDT is the selective drug uptake in
sufficient quantity in given location of the lesion, this can likely
be improved by local drug delivery.
Verteporfin, also known as benzoporphyrin derivative
monoacid ring A is a second generation photosensitizer.
Visudyne R© (Novartis) is a liposomal formulation of Verteporfin
with a short DLI and is clinically utilized for the treatment
of age related macular degeneration and polypoidal choroidal
vasculopathy. Previous reports highlight that Verteporfin can
accumulate in plaque (Hsiang et al., 1993; Allison et al., 1997).
However, studies demonstrating the therapeutic potential
of Verteporfin upon photo activation for the treatment of
atherosclerotic plaque are still lacking. The present study
aims to examine the effect of Visudyne R© mediated PDT on
atherosclerotic plaque as well as optimization of the local
photosensitizer and light delivery within atherosclerotic plaque
to reduce the side effects of treatment.
MATERIALS AND METHODS
Chemicals
Dihydroethidium (DHE), Terminal Transferase from Calf
Thymus (TdT), Digoxigenin-11-UTP, Anti-Digoxigenin-
Rhodamine Fab fragments, phenylephrine, Acetylcholine,
Haematoxylin, Eosin, Oil Red O, and other fine chemicals were
purchased from Sigma (Buchs, Switzerland). Primary antibodies
including F4/80, α-smooth muscle actin, Von Willebrand factor,
appropriate secondary antibodies conjugated to Alexa Fluor
488/546 and Hoechst were obtained from Abcam (Cambridge,
UK).
Photosensitizer
Visudyne R© (PubChem CID:5362420) is commercially available
(Novartis) and 1 g Visudyne R© powder consisted of 15mg
Verteporfin as active photosensitizer. Visudyne R© was dissolved
in 0.9% NaCl and 5% glucose (B. Braun Medical AG, Sempach)
at a concentration of 100, 200, or 500 ng/ml that actually
contained 1.5, 3, or 7.5 ng/ml of Verteporfin. Solutions of the
photosensitizers were prepared fresh and used within 1 h.
Animal Experiments
Seven weeks old male ApoE−/− mice with the C57BL/6 genetic
background weighing 21± 2 g were obtained from Charles River
laboratories, France. The animals were housed in individually
ventilated cages in the animal center facility at University of
Fribourg (Switzerland). All animals received humane care and in
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compliance with the European Convention on Animal Care in
accordance with the Swiss Animal Protection Law after obtained
permission of the State Veterinary Office, Fribourg and approved
by the Swiss Federal Veterinary Office, Switzerland (FR 2013/35).
Animals were maintained on chow diet and water ad libitum in
a controlled environment at a temperature of 20◦C with 40–50%
humidity, 12-h/12-h light/dark cycle. After 1 week of adaptation,
ApoE−/− mice were fed for 16 to 20 weeks with a lipid-rich diet
(0.2% cholesterol and 21% butter, Western U8958 version 35,
SAFE, France).
Atherosclerotic Plaque Characterization
Animals were euthanized; thoracic aorta was dissected and
embedded in Tissue-Tek O.C.T. compound according to
standard procedure. Five micrometers thick serial sections were
cut and stained with Haematoxylin-Eosin (HE) to characterize
the general architecture of the plaques. Intima thickness, media
thickness, necrotic core area and plaque area was determined
on HE stained sections (Khanna et al., 2013; Jain et al., 2015).
The lesion was traced manually and measured using ImageJ
software. Plaque area was defined as the area between innermost
elastin lamina and lumen of the artery. Necrotic core area was
defined as acellular areas in the intima and is represented as
% necrotic core area/plaque area (Thorp et al., 2009). Plaque
lipid was determined by Oil red O staining and is represented
as % Oil red O positive area/plaque area (Khanna et al.,
2013). Morphometric analysis was performed using bright field
microscopy by a Nikon Ni-U microscope (Nikon, Tokyo, Japan)
utilizing the 4x and 20x objectives. Plaque smoothmuscle cell and
macrophage content was determined by immunohistochemical
analysis. Briefly, aortic sections were permeabilized using 0.2%
triton and incubated for 1 h with α-SM actin (Abcam, 1:200) or
F4/80 antibody (Abcam, 1:200) to detect smooth muscle cells
(SMC) and macrophages respectively. Staining was quantified
using the ImageJ software as previously described (Jensen,
2013).
Intra-Arterial Drug Delivery
The mice were anesthetized and sacrificed using Isoflurane in
accordance with an approved protocol. Thoracic aorta (1.5 cm
length) was excised, cleaned and mounted on a cannula made
from blunted 25-gauge hypodermic needles and fixed within
a stainless steel support. The whole assembly was then placed
in the vessel chamber containing Krebs bicarbonate solution
(composition in mM: NaCl 118; KCl 5; CaCl2 2.5; MgSO4 1.2;
KH2PO4 1.2; NaHCO3 25; glucose 11; EDTA 0.03; pH 7.4)
maintained at 37◦C. The vessel holding cannula was connected
to a syringe pump (World Precision Instruments, Sarasota, FL)
and arteries were perfused in the dark with Visudyne R© (100–
500 ng/ml) or vehicle (0.9% NaCl and 5% glucose) for 5–30 min
at a flow rate of 1.2 ml/min (Hayase et al., 2001). Themediumwas
constantly bubbled with 5% CO2 and 95% O2 (Hitchcock et al.,
2010; Prasad et al., 2014). After perfusion, aortic segments were
immediately flushed with vehicle and were embedded in O.C.T.
compound using liquid nitrogen
Visudyne® Uptake
The localization of Visudyne R© within the artery was assessed
on histological sections (5µm) using a Leica TCS SP5
DMI6000 confocal microscope (Leica Microsystems) equipped
with Leica plan apo 20 × (numerical aperture 0.7) dry
objective. The sections were illuminated with 405 nm Diode
laser. Images were collected in the fluorescence emission range
of 650–750 nm. Elastin auto fluorescence was co-detected upon
excitation with 488-nm laser light. Pictures were taken by
using Leica Application Suite Advanced Fluorescence (LASAF)
software (Leica Microsystems). Mean fluorescence intensity was
quantified and normalized with respect to the area of tissue using
the ImageJ software as previously described (Jensen, 2013).
Light Source and Delivery
Intra-arterial PDT was performed immediately after Visudyne R©
(500 ng/ml) perfusion using a cylindrical light diffuser that is an
optical fiber based catheter (RD20, Medlight SA, Switzerland).
The proximal end of the diffuser is coupled to a 1W Diode-
pumped solid-state laser (Frankfurt Laser Company, Germany)
emitting at 690 nm. The distal extremity of diffuser is a 20 mm
long illumination tip. Laser powers emitted by the cylindrical
light diffusers were calibrated using an integration sphere, by
comparison with a frontal light diffuser (FD-1, Medlight SA,
Switzerland) delivering 150 mW measured with a power-meter
(Spectra-Physics Newport; model 407A; Borle et al., 2003). The
illumination tip of the light diffuser was inserted into the lumen
of the artery via the cannula through which Visudyne R© was
perfused. Total light doses of 100 J/cm2 or 200 J/cm2 were applied
at an irradiance of 334mW/cm2. After PDT, the aorta was
removed from the cannula and divided into two parts. The
proximal part was immediately snap-frozen and used for ROS
detection. The distal part was kept in Dulbecco’s Modified Eagle
Medium supplemented with 10% FBS and antibiotics (100U/ml
penicillin and 100µg/ml streptomycin) and incubated at 37◦C
for 24 h to assess the influence of PDT on apoptosis, a late-stage
event.
To characterize the dose and time related uptake of
Visudyne R© as well as to assess the influence of Visudyne R©-PDT,
laser irradiations only or combination of both on atherosclerotic
plaque, animals were divided into (1) Vehicle (5% glucose
in normal saline) treated control, (2) Vehicle treated, laser
irradiated (200 J/cm2) group, (3) Non-irradiated Visudyne R©
treated groups, (4) Visudyne R© treated, laser (100 J/cm2)
irradiated group (5) Visudyne R© treated, laser (200 J/cm2)
irradiated group (Figure 1).
Detection of ROS
Aortic superoxide content was determined by Dihydroethidium
(DHE) staining. In the presence of superoxide, DHE is oxidized
to ethidium that intercalates with DNA and becomes fluorescent.
Briefly, aorta sections were rinsed with PBS and incubated with
DHE (10µM) in a dark humidified chamber for 10 min at 37◦C.
The sections were then washed with PBS and counterstained
with Hoechst (5µg/mL; He et al., 2016). Fluorescent images were
acquired with same exposure time for all sections from different
groups on a Nikon Ni-U microscope (Nikon, Tokyo, Japan).
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FIGURE 1 | Schematic representation of the ex-vivo artery perfusion system where atherosclerotic aorta, isolated from ApoE−/− mice, was mounted
over a cannula and perfused with vehicle or Visudyne® for 5–30min. Laser irradiation at 100 or 200 J/cm2 was performed immediately after perfusion. ROS
level and apoptosis was monitored immediately or after 24 h of laser irradiation respectively.
DHE fluorescence density was measured using ImageJ software
after subtracting auto-fluorescence from elastic lamellae (Raaz
et al., 2015).
Detection of Apoptotic Cells by Tunel
Staining
Apoptotic cells within the aortic segments were detected
by terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) 24 h after PDT (Gad et al.,
2001). Briefly, aortic sections were permeabilized with 0.2%
Triton and subsequently incubated for 30min at 37◦C in
a humidified chamber in the TUNEL reaction mixture
containing Digoxigenin-11-UTP. Incorporated digoxigenin
was detected using rhodamine-conjugated anti-digoxigenin
antibody. Apoptotic cells were detected and quantified using
ImageJ software as described previously (Veurink et al., 2003).
Percentage of apoptotic cells/total cells was determined in
the entire section, and either only in plaque or only in media
beneath plaque. For identification of apoptotic macrophages,
double-immunostaining was performed as described previously
(Ray et al., 2000). In brief, after TUNEL staining, sections
were rinsed with PBS and incubated with primary antibody for
F4/80 (1:100) at room temperature for 60min. The sections
were washed and labeled with appropriate secondary antibody
conjugated with Alexa fluor 488 for 30min followed by staining
of nuclei with Hoechst (5µg/mL) for 10min. The sections were
examined under a fluorescence microscope and the percentage
of apoptotic macrophages of the total number of cells was
determined. Two fields were selected to cover almost entire tissue
section.
Assessment of Vascular Function
Vascular reactivity was assessed after 24 h on arterial segments
treated in a similar way as described above. After 24 h of
treatment, aortic segments were cut into rings (2mm in
length) and mounted between two L shaped hooks in a Multi-
Myograph System (Model 720 MO, Danish Myo Technology
A/S, Denmark). Myograph chambers were filled with Krebs
bicarbonate buffer and were bubbled with 95% O2 and 5%
CO2 at 37
◦C. Changes in isometric tension were recorded with
Lab Chart Pro v8.0.5 software (AD instruments, UK). The
rings were progressively stretched to a passive tension of 5mN
and were allowed to equilibrate for 60min during which the
Krebs buffer was changed every 15min. The resulting tension
after equilibration period represented the base line value. In
order to assess the maximum tissue contractility and viability,
the rings were maximally contracted with 80mM KCl Krebs
solution and change in tension (1mN) was recorded. After
the assessment of maximum tissue contractility, rings were
washed and rested for 15–20min so that tension returns to the
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baseline. Cumulative dose response curve to phenylephrine (PE;
1 nm–100µM) was then taken (Khanna et al., 2011; Jain et al.,
2012). Vasoconstriction response to PE was expressed as the
increase in force (1mN) from base line upon cumulative addition
of different doses of PE. To assess endothelium dependent
relaxation, aortic rings were washed and subsequently pre-
constricted with a submaximal concentration of PE (inducing
60–80% of maximal vasoconstriction). Rings were then exposed
to cumulative doses of Acetylcholine (Ach; 3 nM–300µM; Jain
et al., 2016). Relaxation response to Ach was expressed as the
net decrease in force (1mN) generated by submaximal PE.
Vasoconstriction and vasodilation responses were normalized
with respect to per mm length of aortic rings. Since in the present
study, smooth muscle contraction was substantially reduced, we
also calculated percentage relaxation (decrease in submaximal
PE induced contraction upon addition of Ach/Submaximal PE
induced contraction × 100) in order to normalize the reduced
contractility.
Statistical Analysis
All experiments were performed at least three times. The results
are presented and expressed as the Mean ± Standard deviation.
The significance of difference among groups was analyzed by
one way analysis of variance (ANOVA) followed by Bonferroni
post-hoc test using GraphPad Prism version 5.0 (GraphPad
Software, La Jolla, CA). p < 0.05 were considered statistically
significant.
RESULTS
Analysis of Plaque Composition
Localization of the photosensitizer within the atherosclerotic
plaque could vary significantly depending on multiple
parameters including the type of lesion, its location and
stage of development. We therefore characterized the plaque
composition within the thoracic aorta of ApoE−/− mice. Gross
examination of the atherosclerotic plaques used in the present
study revealed high plaque lipid content, large necrotic cores,
few calcium deposits, and medial destruction (Figure 2, Table 1).
Immunohistochemistry data demonstrated that the lesions
mainly consisted of macrophage with well-formed but thin
fibrous cap containing SMC and the lesions were lined with
endothelial cells (Figure 2, Table 1).
Dose Dependent Accumulation of
Visudyne®
To determine the optimal dose of photosensitizer, three
concentrations of Visudyne R© i.e., 100, 200, and 500 ng/ml (1.5,
3.0, and 7.5 ng/ml Verteporfin as active photosensitizer) were
perfused in the isolated aorta for 15min. Fluorescence imaging
of the artery sections demonstrated characteristic fluorescence
of Visudyne R© (Figure 3A). Exposure of the atherosclerotic aorta
to increasing concentrations of Visudyne R© demonstrated a dose
dependent increase in fluorescence intensity (Figure 3B). Weak
fluorescence observed at 100 ng/ml (FI: 5.5 ± 3.2) was enhanced
by 4.8-fold at 200 ng/ml (F: 31.9 ± 3.2) or 6.8-fold at 500 ng/ml
(FI: 42.9 ± 3.4). Visudyne R© uptake at 500 ng/ml concentration
was significantly higher than 200 ng/ml concentration and was
therefore used for further studies.
Time-Dependent Visudyne® Accumulation
Perfusion with Visudyne R© (500 ng/ml) demonstrated a time-
dependent increase in fluorescence (Figure 4A). Quantification
of the fluorescence intensity revealed Visudyne R© accumulation
as early as after 5min of treatment (FI: 9.8 ± 2.5). This
accumulation increased at 10min (FI: 23.7 ± 3.0). The maximal
FIGURE 2 | Plaque composition in ApoE−/− after 16-20 weeks of lipid-rich diet feeding. Representative microscopic images stained with (A)
hematoxylin-eosin and (B) Oil red O demonstarting general architecture and lipid content of the plaque respectively. Plaques were analyzed by immunohistochemistry
for the presence of (C,D) α-SM-actin, (E,F) Macrophage (F4/80), and (G,H) endotheium (vWF), where (D,F,H) are respective images merged with green elastin auto
fluorescence and blue fluorescence of Hoechst stained nuclei. Scale bar in A = 100 µm and applies to (A–H) (n = 7).
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TABLE 1 | Plaque composition from thoracic aorta sections of ApoE−/− mice fed with a lipid-rich diet for 16–20 weeks.
Intima Media Intima/media % Necrotic Plaque % Oil red O % Plaque % Macrophage
thickness (µm) thickness (µm) thickness ratio core area area (µm2) positive area SMC
174.4 ± 51.7 47.2 ± 6.8 3.9 ± 1.2 17.8 ± 3.2 11168 ± 2705 23.0 ± 5.8 21.5 ± 6.2 63.4 ± 11.1
Results are mean ± SD from (n = 7).
fluorescence was observed after 15min of treatment (FI: 42.9
± 3.4), while 30min exposure showed no further increase in
fluorescence (FI: 39.3 ± 2.4; Figure 4B). Since FI after 15min
was comparable to 30min treatment, we have therefore chosen
the 15min time point as optimal treatment time for the light
activation.
Visudyne®-PDT Stimulated ROS
Generation
ROS levels were monitored using DHE staining (Figure 5A).
DHE fluorescence intensity in vehicle treated, laser irradiated
(200 J/cm2; FI: 10.6 ± 2.6) was slightly increased as compared
to only vehicle treated control (FI: 4.5 ± 4.0). ROS level in
Visudyne R© treated groups was not affected when the irradiation
dose was zero (FI: 6.9± 1.8). A 4.5-fold increase in ROS levels was
observed in Visudyne R© photo irradiated arteries at 100 J/cm2 (FI:
25.3 ± 5.5) as compared to vehicle treated control (Figure 5B).
ROS levels further increased by 8.4-fold upon increasing the light
irradiation dose to 200 J/cm2 (FI: 43.4 ± 13.9), indicating the
dependence of ROS production on light dose.
Visudyne®–PDT Induces Apoptosis of
Plaque Cells
After PDT, the aorta was incubated for 24 h to assess the
influence of PDT on apoptosis (Figure 6A). Quantitative analysis
of TUNEL staining demonstrated that the percentage of total
apoptotic cells was not significantly different among vehicle
treated laser irradiated groups (2.4 ± 3.1%) or only vehicle
treated groups (2.9 ± 1.7%). A similar degree of apoptosis
(2.5 ± 1.6%) was noted in Visudyne R© treated groups when
the irradiation dose was null indicating no dark cytotoxicity of
Visudyne R© (Figure 6B). A large increase in TUNEL positive cell
percentage was noted in Visudyne R© treated arteries illuminated
at 100 J/cm2 (41.3 ± 15.3%). The percentage of apoptotic cells
significantly increased while increasing the laser irradiation
dose to 200 J/cm2 (58.9 ± 4.6%; Figure 6B). A more detailed
examination revealed that apoptotic cell percentages were higher
within the plaque, encircled and marked as P (1.3 ± 0.9, 25.2 ±
2.1, 44.9 ± 6.0%) as compared with medial wall beneath plaque,
encircled and marked as M (0.5± 0.2, 8.5± 4.7, 15.3± 12.7%) at
light doses of 0, 100 or 200 J/cm2, respectively (Figures 6A,B).
Visudyne®-PDT Preferentially Affects
Plaque Macrophages
Immunostaining of macrophages using F4/80 antibody revealed
high content of macrophages (63.4 ± 11.1%) within the
plaques. Double immunofluorescence staining showed negligible
apoptosis of macrophages in Visudyne R© treated arteries
that underwent no irradiation. Out of the total number
of cells, only 0.3 ± 0.2% cells were F4/80+ TUNEL+
while most of the macrophages were not apoptotic i.e.,
F4/80+ TUNEL− 64.3 ± 7.3% (Figures 7A,B). A significant
increase in F4/80+ TUNEL+ cell population was evident
in Visudyne R© treated arteries illuminated with 100 J/cm2
(37.6 ± 6.4%) or 200 J/cm2 (45.3 ± 5.4%) leading to a
significant reduction in non-apoptotic macrophages (26.9 ±
11.4%, 21.5 ± 2.3% at 100 J/cm2 and 200 J/cm2, respectively,
Figures 7A,B). Importantly, macrophages contributed 80.1 ±
5.6% of total apoptotic cells in plaque, indicating that apoptosis
of macrophages was more frequent after Visudyne R©-PDT.
Visudyne®-PDT Attenuated Vascular
Function
The effect of PDT on vascular function was assessed 24 h after
treatment using Myogram. Maximal tissue contractility induced
by KCl was similar among vehicle only (2.4± 0.6mN), laser only
(2.4 ± 0.06mN) and Visudyne R© only (2.3 ± 0.2mN) treated
groups. A significant reduction in vasoconstriction was observed
upon laser irradiation of Visudyne R© treated arteries at 100 J/cm2
(1.6± 0.3mN) or 200 J/cm2 (0.8± 0.4mN; Figure 8A). Likewise
PE induced maximal contraction was similar between vehicle
only (2.4 ± 0.2mN), Visudyne R© only (2.5 ± 0.6mN) and
laser only (2.0 ± 0.3mN) treated groups and were significantly
reduced upon laser illumination of Visudyne R© treated arteries
at 100 J/cm2 (1.1 ± 0.5mN) or 200 J/cm2 (0.5 ± 0.4mN;
Figure 8B). Similarly, Ach induced maximal relaxation was
significantly reduced in Visudyne R© treated arteries irradiated
at 100 J/cm2 (1.0 ± 0.7mN) or 200 J/cm2 (0.2 ± 0.3mN) as
compared to only Visudyne R© treated groups (2.3 ± 0.8mN).
Ach induced vasorelaxation in laser alone (2.3 ± 0.2mN) or
vehicle treated groups (2.2 ± 0.3mN) was comparable to only
Visudyne R© treated groups (Figure 8C). Percentage relaxation in
Visudyne R© treated arteries (87± 12%) was only slightly reduced
upon laser irradiation at 100 J/cm2 (78 ± 19%) or 200 J/cm2
(72± 25%).
DISCUSSION
We report here that local arterial perfusion for a short period
of time can lead to a high accumulation of Visudyne R©
in atherosclerotic plaque. Subsequent intra-arterial photo-
activation of Visudyne R© induces significant apoptosis of
plaque macrophages. Moreover, Visudyne R©-PDT attenuates
the vascular functionality of smooth muscle cells. Therefore
local Visudyne R©-PDT could be effective for management of
atherosclerosis and restenosis.
The role of PDT in the prevention of catastrophic events
in atherosclerosis is well established. Previous studies utilizing
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FIGURE 3 | Dose dependent Visudyne® uptake. Excised aorta from ApoE−/− mice were perfused for 15min with 0 (n = 6), 100 (n = 3), 200 (n = 3), or 500 ng/ml
(n = 8) of Visudyne®. (A) Arterial sections were excited with 405 nm light and fluorescence emission was measured between 650 and 750 nm. Upper panel illustrates
characteristic fluorescence of Visudyne® in red and lower panel is merged image with auto-fluorescence of elastin. Scale bar: 50 µm. (B) Bar graph representing the
Mean fluorescence intensity in each group. *P < 0.001 vs. 100 ng/ml, #p < 0.001 100 ng/ml vs. 200 ng/ml, $p < 0.001 200 ng/ml vs. 500 ng/ml.
FIGURE 4 | Time dependent Visudyne® uptake. Aorta isolated from ApoE−/− mice were treated with Visudyne® (500 ng/ml) at different time intervals. (A)
Representative sections demonstrating Visudyne® accumulation at 5 (n = 4), 10 (n = 4), 15 (n = 8) and 30min (n = 4). Scale bar: 50µm. (B) Bar graph representing
the mean fluorescence intensity after 5–30min of treatment. *P < 0.001 vs. 5min, #p < 0.001 5 vs. 10min, $p < 0.001 10min vs. 15min.
FIGURE 5 | ROS production by Visudyne® mediated PDT. (A) Fluorescent photomicrograph of Dihydroethidium staining in aortic sections from vehicle (n = 6),
laser only (n = 4), Visudyne® only (n = 4), Visudyne® treated, laser (100 J/cm2; n = 6) or Visudyne® treated, laser (200 J/cm2; n = 6) treated groups. Upper panel
shows ROS signals as red fluorescence and lower panel represents the merged image with green elastin auto fluorescence together with blue fluorescence of the
Hoechst stained nuclei. Scale bar: 100µm. (B) Bar diagram representing DHE fluorescence intensity/µm2. *P < 0.05 vs. 0 J/cm2, #p < 0.01 100 vs. 200 J/cm2.
Photofrin (Hsiang et al., 1995) or 5-aminolevulinic acid
(Peng et al., 2011) have demonstrated that PDT can inhibit
atherosclerotic plaque progression. An in vivo study conducted
by Hayase et al. showed that Motexafin lutetium based PDT
promotes stabilization by decreasing plaque macrophage content
(Hayase et al., 2001). Photosensitizers are generally administered
via systemic injection that may lead to inconvenient cutaneous
photosensitivity such as erythema and oedema lasting up
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FIGURE 6 | Visudyne®-PDT induced apoptosis of plaque cells. (A) TUNEL assay was performed after 24 h in arteries treated with vehicle (n = 5), laser only (n =
4), Visudyne® only (n = 6), Visudyne® treated, laser (100 J/cm2; n = 5), or Visudyne® treated, laser (200 J/cm2; n = 4) treated groups. Upper panel shows TUNEL
positive cells and are indicated by red fluorescence and lower panel is merged images with Hoechst (blue) and elastin (green) auto fluorescence. The plaque area is
encircled with white dotted line and marked as P, while the media beneath plaque is marked as M and encircled by red dotted line. Scale bar: 100 µm. (B) Bar
diagram representing the percentage of TUNEL-positive cells in total vessel, plaque or in media beneath plaque. *P < 0.05 vs. vehicle treated groups, #p < 0.01 100
vs. 200 J/cm2, $p < 0.001 plaque vs. media beneath plaque.
to 3 months, in some cases (Braathen, 2014), as well as
limited accumulation in the specific region of interest. Selective
accumulation of the photosensitizer is critically important for the
success of PDT. As a result, the intra-arterial, local drug delivery
approach has been chosen to minimize systemic exposure to
the drug and to attain high therapeutic concentration of the
photosensitizer directly on the plaque within short treatment
time compatible with the surgical interventions.
Verteporfin is a potent, second-generation, FDA approved
photosensitizer with minimal skin photosensitization.
Verteporfin is activated by 690 nm photons, allowing for
sufficient light penetration and drug activation. It binds with
endogenous low density lipoproteins (LDL) and is significantly
more cytotoxic against non-adherent cells as compared to
Hematoporphyrin derivative (Richter et al., 1987). Previous
reports suggest that Verteporfin-based PDT might prevent the
development of intimal hyperplasia (Adili et al., 1998). However,
studies evaluating anti-atherosclerotic efficacy were still lacking.
In the present work, local delivery of Visudyne R© into the plaque
of atherosclerotic aorta has been achieved via an ex vivo approach
based on a modified system described previously (Zulliger et al.,
2002; Prasad et al., 2014). The ex vivo approach reduces the
complexity of in vivo system and provides a near physiological
environment. This ex vivo approach also enabled us to perform
intra vascular light activation of the photosensitizer localized in
the plaque. Since Visudyne R© accumulation reaches saturation
after only 15 min of treatment. We have therefore selected this
relatively short time as optimal treatment time for the laser
irradiation. DLI is an important parameter that governs the
efficacy and selectivity of vascular damage that occurs during the
treatment. A short DLI is clinically desirable to facilitate a single
treatment in the patient or day-patient clinic that otherwise is
limited to treating patients at some interval after angioplasty with
possible undesired complications of repetitive invasive injury.
Previously, P. Gonschior et al. demonstrated the possibility of
reducing DLI using a local delivery approach (Gonschior et al.,
1996). Local delivery of Photofrin (5mg in 2mL over 30 s) was
performed in porcine arteries using a macro-porous balloon
catheter. Intra-vascular illumination with an argon-dye laser
reduces myointimal hyperplasia after arterial injury (Gonschior
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FIGURE 7 | Visudyne®-PDT mediated macrophage apoptosis. (A) Representative images showing TUNEL-positive signal (green), F4/80-positive (red), Hoechst
(blue), and merged image in Visudyne® treated arteries photoirradiated with 0 J/cm2 (upper panel, n = 3), 100 J/cm2 (middle panel, n = 3), or 200 J/cm2 (lower
panel, n = 4). Scale bar: 25µm. (B) Percentage of apoptotic macrophages was assessed as the percent of TUNEL+ F4/80+ cells to the total number of cells. *P <
0.001 vs. 0 J/cm2.
FIGURE 8 | Visudyne®-PDT reduces vascular function. Aortic segments devoid of plaque from different treatment groups were mounted in Myograph. (A) Bar
diagram representing KCl induced contraction (B) Dose-dependent phenylephrine (1 nM–100µM) induced contractions and (C) Acetylcholine (3 nM–300µM)
mediated relaxations. Results are mean ± SD (n = 4). *p < 0.05 vs. Visudyne®.
et al., 1996). Likewise Hayase M, et al. showed that activation of
Motexafin lutetium after 15 min of local infusion reduces plaque
burden. Motexafin lutetium was applied by using a drug delivery
balloon catheter where it was infused for 15 min directly over
the plaque in rabbit atherosclerotic artery (Hayase et al., 2001).
Local delivery also enabled to cut the total dose required to about
one tenth to that of systemic dose. The findings of the present
study showed that local delivery can result in high accumulation
of Visudyne R© in the plaque within a short application time, thus
supporting the feasibility of Visudyne R© mediated PDT under
clinical conditions.
Efficient and accurate delivery of light to the target tissues
is particularly important. The best way to achieve suitable
illumination is through endovascular light delivery. Endo-
luminal photo activation of Visudyne R© was achieved using a
cylindrical light diffuser which being at the center of the vessel’s
lumen, thus providing a homogenous and precisely controlled
light dosimetry. It should be noted that the distribution of the
light throughout the thickness of the plaque is not fully uniform.
This could also account for more apoptosis of plaque cells when
the photosensitizer is activated via an inside-out approach.
Upon illumination, photosensitizer molecules absorb light
and start reactions eventually generating hydroxyl radical,
superoxide anion, hydrogen peroxide (Type I PDT), and singlet
oxygen (Type II PDT). Singlet oxygen can further react with
nearby molecules to induce the formation of other ROS species
that could be detected via chemical sensors like DHE (Satoh
et al., 2010; He et al., 2016). When ROS concentration surpasses
a certain level it leads to apoptosis via loss of mitochondrial
membrane potential, lipid peroxidation, or protein denaturation
of cellular membranes and organelles (Chen et al., 2001; Wang
and Yi, 2008). Increasing ROS levels is widely utilized in multiple
therapeutic approaches like radiotherapy, chemotherapy and
PDT for the destruction of leukemia cells (Chou et al., 2004;
Wang and Yi, 2008) or macrophages (Zhu et al., 2015). The
amount and micro-localization of ROS is dependent on the
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concentration and supply of oxygen in the tissue and possibly
also on the irradiation intensity and fluence rate. This indicates
that it is important to assess light dose effects for effective
treatment. A light dose dependent increased ROS level leading
to 50–60% apoptosis was noted following photo activation
of Visudyne R©. Our results demonstrate that locally delivered
Visudyne R© in the absence of light does not alter the apoptosis,
indicating no dark toxicity of the photosensitizer. These findings
are in agreement with previous reports where Verteporfin alone
below 100 ng/ml concentration does not exerts any cytotoxic
effects in Retinoblastoma Cell Lines (Stephan et al., 2008).
Furthermore, our data show that Visudyne R©-PDT resulted in a
higher apoptosis of plaque cells as compared to part of the media
which was covered by plaque. A possible explanation for such a
differential effect could be made on the basis of inherent property
of Verteporfin to preferentially localize in plaque (Hsiang et al.,
1993; Allison et al., 1997). BA Allison et al. used a mutant
fibroblast cell line which has no LDL receptors to demonstrate
that LDL receptors are responsible for the accumulation
of lipoprotein-associated Verteporfin (Allison et al., 1994).
LDL receptors being present on macrophages (Hansson and
Hermansson, 2011) may be involved in the uptake of Visudyne R©
which is a liposomal formulation of Verteporfin. PDT using
porphyrins or texaphyrin derivatives like Lutetium texaphyrin,
or 5-aminolevulinic acid, have previously been shown to reduce
plaque macrophages resulting in stabilization of atherosclerotic
plaques and reduction of plaque inflammation (Hayase et al.,
2001; Peng et al., 2011). We therefore further investigated the
effect of PDT on plaque macrophages. Our results demonstrated
that the bulk of apoptotic cells were macrophages. Phagocytic
cells like macrophages possess a powerful ROS generating system
in response to stimulation with various agents (Forman and
Torres, 2001; Swindle et al., 2002; Italiani and Boraschi, 2014).
It could thus be assumed that macrophages were more efficient
in PDT induced ROS production and were therefore more
susceptible to apoptosis. Another possible explanation could in
relation with the plaque composition. Atherosclerotic plaques in
the present study were characterized by thin fibrous cap with high
macrophage population (63% of total cells). Since PDT induces
inflammation, which in turn causes the tight junctions between
endothelial cells to let leukocytes pass, hence Visudyne R© can
easily get to the macrophages (with high probability to come in
contact with the photosensitizer) in the plaque. Since the ROS
produced by activated photosensitizer have very short diffusion
distance (<100 nm), PDT induced apoptosis is restricted to cells
with adequate presence of photosensitizer like the macrophages
in this case.
During atherogenesis, SMC undergo phenotypic switching
from the contractile to the synthetic state. SMC migrate from
media to intima where they proliferate and contribute to
other cellular processes such as inflammation, apoptosis, and
matrix alterations (Dzau et al., 2002) that in turn aggravate
atherosclerosis progression. Prominent vascular effects occur
during and after PDT. Although there are no clear reports
demonstrating the phenotypic modulation of SMC immediately
after PDT, experimental evidence point to the fact that PDT by
producing cytotoxic free radicals results in localized depletion
of SMC (Granville et al., 2001) that eventually leads to initial
reduction in plaque SMC content (Waksman et al., 2008; Peng
et al., 2011). Such depletion of SMC in themedial wall is beneficial
in preventing neointimal hyperplasia (Nyamekye et al., 1996;
Nagae et al., 2001) or atherosclerosis (Peng et al., 2011). This
is followed by repopulation of plaques with a non-proliferating
quiescent SMC (Waksman et al., 2008). Moreover, PDT induced
injury to SMC does not induce an inflammatory response
in the vessel wall (Statius van Eps et al., 1997) but reduces
basic fibroblast growth factor content thereby inhibiting invasive
SMC mitogenesis to favorably alter the vascular injury response
(Statius van Eps et al., 1997). We therefore examined the effect
of Visudyne R©-PDT on the viability and functionality of medial
SMCs. Indeed, our data using Myogram demonstrated that the
viability and contractility of SMCs was significantly reduced
following Visudyne R©-PDT. In the present study, we used Ach to
study the influence of PDT on endotheliummediated relaxations.
Ach receptors are expressed on endothelial cells of blood vessels
and their activation results in increased intracellular calcium
and generation of endothelium-derived relaxing factors (EDRF)
such as nitric oxide which induce relaxation of the adjacent
vascular SMC (Coats et al., 2001). Since phenylephrine induced
smoothmuscle contractions were substantially reduced following
Visudyne-PDT, an expected reduction in Ach induced net
relaxation was observed. However, it remains unclear whether
such reduction in relaxation response is due to dysfunctional
SMC or dysfunctional endothelium. We therefore calculated
percentage relaxation by normalizing the net contraction induced
by submaximal phenylephrine where a modest reduction in
endothelium dependent vasorelaxation was observed. These
results corroborated with previous reports where PDT using
Photofrin as a photosensitizer impairs the production or release
of EDRF by the endothelium (Gilissen et al., 1993). Previous
reports also suggest that singlet molecular oxygen, superoxide
anion radical, H2O2 and hydroxyl radical, generated during PDT
are involved in not only supressing the noradrenaline induced
contraction but also impairs endothelium-dependent relaxation
evoked by acetylcholine (Mizukawa and Okabe, 1997). Our
results indicate that Visudyne R©-PDT could induce the apoptosis
of plaque macrophages and at the same time could reduce the
function of the vascular smooth muscle cells.
CONCLUSION
This study demonstrated that local drug delivery can result
in high accumulation of Visudyne R© within atherosclerotic
plaque shortly after the drug administration. Intra-arterial light
activation induces significant apoptosis of plaque macrophages.
A short DLI offered by local Visudyne R© application can be
effectively utilized for treatment of atherosclerotic plaque in
conjunction with PCI procedures.
STUDY LIMITATIONS
The study was conducted in mouse model of atherosclerosis.
Although the lesions of ApoE−/− mice resemble many of
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the characteristic of human atheroma, yet the plaque stiffness,
muscularity, and thickness vary to a great extent between mouse
aorta and human coronary artery. Although previous reports
documented the feasibility of intracoronary PDT in porcine
model (Waksman et al., 2006) as well as in human subjects
(Kereiakes et al., 2003), precautions must be taken to use drug
delivery catheters and diffusers suitable to the geometry of the
vessel particularly in the case of highly occluded vessels in
order to allow smooth insertion and to avoid any mechanical
damage to the vessel walls. Further studies in large animal models
having plaque more similar to humans are therefore warranted
to investigate long term effect in particular the late effects of
Visudyne R©-PDT in terms of plaque composition and plaque
stabilization/regression.
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